-Bloomberg
Guggenheim Initiates Coverage On Johnson & Johnson with Neutral Rating, Announces Price Target of $161
Guggenheim analyst Vamil Divan initiates coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and announces Price Target of $161.